Quarterly report · Q2
3341.TEDINET S100PM0M
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥152.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥299.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥146.2bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥2.8bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥2.4bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥2.8bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥6.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.5bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.9bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥2.4bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.7bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.3bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥1.3bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥187.6bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥178.8bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥184.4bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥133.6bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥125.9bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥54.0bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥52.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥50.8bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥21.5bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥25.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥21.5bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥25.5bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥27.8bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥32.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥19.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥10.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥7.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥9.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥5.0bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥2.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥17.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥10.9bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥53.66 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥40.62 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.56 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥44.71 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.44 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 28.8% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.6% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 37
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥7.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥7.0bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥3.3bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥136.2bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥136.2bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1m |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥6.0bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥9m |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥500m |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥19.2bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥12.2bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥7.0bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥396m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥159.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥152.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥7.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥6.1bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥9.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥9.9bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥3.3bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥128.7bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥128.7bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥5.0bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥3.6bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥3.6bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥5m |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥440m |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥23.7bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥9.9bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥195m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥156.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥146.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥9.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥5.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 515
| Item | Context | Value | Unit |
|---|---|---|---|
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |